CRUK TET BETA
Start date
01 February 2026End date
31 July 2027Overview
Bowel cancer is a leading cause of cancer-related mortality in England. Biennial Faecal Immunochemical Test (FIT) screening can reduce bowel cancer-related deaths by detecting cases before symptoms develop. However, uptake remains suboptimal, particularly among men. Evidence from a single-centre study in Scotland suggests that a brief intervention, akin to patient navigation, delivered to men attending routine abdominal aortic aneurysm (AAA) screening appointments, can facilitate participation.
The overarching aim of this study is to evaluate the efficacy, feasibility, acceptability and cost-effectiveness of implementing patient navigation intervention across multiple AAA screening services in England.
This study will be a single-arm, multi-centre feasibility study that will be conducted across five AAA screening centres in England:
- Leicester
- Birmingham and Black Country
- London
- West Yorkshire
- Somerset and North Devon.
Over a three-month period (November–February 2026), AAA screening practitioners will deliver patient navigation to a sample of approximately 4190 men, aged 65+ years, who attend AAA screening and self-report as bowel screening non-responders.
Aims and objectives
The aims of this research are to:
- Assess the efficacy of delivering patient navigation, during AAA screening (Work Package 1)
- Assess the feasibility of delivering patient navigation, during AAA screening (Work Package 2a and 2b)
- Assess the acceptability of delivering patient navigation, during AAA screening (Work Package 3a and 3b)
- Assess the cost-effectiveness of delivering patient navigation, during AAA screening (Work Package 1)
- Develop an implementation toolkit for the intervention, with the aim of supporting future adoption / roll out.
Public Privacy Notice: Using patient navigation to support bowel screening in AAA attendees.
Context: The aim of this study is to find out whether talking to men about bowel cancer screening, during a routine health appointment, is an effective way of supporting them to take part in bowel screening.
A healthcare professional will talk to them during their routine abdominal aortic aneurysm (AAA) screening appointment. We think this may be a good time to talk to them as they are already having conversations about their health during these appointments.
The NHS is keen to improve bowel screening participation among men as they are less likely to participate than women, and they are also more likely to get bowel cancer in their lifetime. Bowel screening can help find cancer before symptoms develop, and often at a time when it is easier to treat and chances for survival improved.
The research: Healthcare professionals, called AAA screening practitioners, in five centres in England will talk to men, aged 65+ years, who attend AAA screening at one of five centres in England: Birmingham and Black Country; Leicester; London; Somerset and North Devon; West Yorkshire. Practitioners will ask patients whether they have recently taken part in bowel screening, and, where they haven’t, offer practical advice and support should they want it. They will also order a new bowel screening kit for the patient, or provide contact details so the patient can request a kit themselves.
What information do we use? To find out whether these conversations lead to more men taking part in bowel screening, we need to use some information about them. The following describes how we will use your data, if you are a participant in the research.
The AAA screening centres will securely send your identifiers (i.e. name, NHS number and date of birth) to NHS England so that NHS England can check your bowel screening activity before and after your AAA screening appointment. They will also share your name and address with a mailing company called ‘DocMail’, so that a survey about your experience discussing bowel screening can be sent to you by post.
NHS England will also look at your age, postcode, ethnicity, and whether you are someone who requires reasonable adjustments. This data about you will then be anonymised and shared with the research team at the University of Surrey. We require this information so we can see whether these conversations work for everyone, or only specific age groups, ethnicities and postcode sectors.
The purposes of the processing: The purpose of this study/processing of the data is to see whether those who discussed bowel screening with a AAA screening practitioner went on to request and/or complete a new bowel screening kit. This will tell us to whether we should try and implement these conversations to other AAA screening centres.
The lawful basis for the processing: The lawful basis for processing personal data, for this study, under the UK General Data Protection Regulation (GDPR), is ‘Legitimate interests’. This is referred to as ‘Article 6.1.f.’ of the GDPR.
The legitimate interests for processing: The legitimate interest in processing personal data for this study is to improve early detection of bowel cancer by increasing participation in bowel screening, particularly among groups with lower uptake, and to support more equitable access to cancer screening.
The categories of personal data obtained: We will receive de-identified, individual-level patient data. This means that we will be able to look individual patients’ data but will not know their identities. This is often referred to as ‘anonymous data’. It ensures patient confidentiality is maintained. The categories of data we will receive include special categories of personal data (sensitive data), including ‘Health data’ and ‘Ethnic origin’.
The recipients of the personal data: The recipients of the personal data will be researchers employed at the University of Surrey. The personal data will be restricted to those conducting the research, namely: Dr Robert Kerrison (Associate Professor in Cancer Care), Dr Sarah Beck (Research Fellow in Cancer Care), and Professor Katriina Whitaker (Professor of Psychology).
Retention period: The University of Surrey will retain all anonymised data for 10 years following the end of the study, in line with the University of Surrey’s research data management policy.
The rights available to individuals in respect of the processing: As the data are deidentified, it is not possible for us to process requests to remove individuals from the data being processed. If you would like to discuss the research with the principal investigator, please contact Dr Robert Kerrison at: r.kerrison@surrey.ac.uk
The right to lodge a complaint with a supervisory authority: You have the right to lodge a complaint with the University of Surrey. To do this, please contact the University of Surrey School of Health Science’s Director of Research, Professor Emma Ream: e.ream@surrey.ac.uk
The sources of the personal data: The sources of the personal data used in this research are obtained from the AAA, and Bowel Screening Programme.
The data provider: The data will be provided by NHS England.
The name and contact details of the data provider’s representative: The contact details for NHS England’s representative (the data provider): data.applications@nhsdigital.nhs.uk
Funding: This study is funded by Cancer Research UK. The funder will not have access to the data.
Funding amount
£109,246.00
Funder
Team
Principal investigator
Dr Robert Kerrison
Associate Professor and Co-Lead for Cancer Care
See profileCo-investigators
Professor Katriina Whitaker
Professor of Psychology and Co-Lead for Cancer Care
See profile
Dr Sarah Beck
Research Fellow and Health Psychologist
See profile